-
Behavioural scienceAdherence and persistence confirms
Older adults starting GLP-1 drugs were younger and heavier than other initiators
Among 58,754 adults aged 65 and over with type 2 diabetes, mean BMI at initiation was 33.8 for GLP-1 drugs as compared to 29.7 for SGLT2 inhibitors.
Preprint · not peer-reviewed -
Health todayHeart and stroke confirms
US deaths recording both type 2 diabetes and cardiac arrest rose faster after 2014
Deaths of US adults recording both type 2 diabetes and cardiac arrest rose by 2.72% a year to 2014, then by 9.55% a year to 2020.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
Overweight/obesity in German children stands at 16.1%, unchanged over two decades
Measured height and weight in a representative sample of 3,978 German children aged 4 to 17 gave an overweight and obesity prevalence of 16.1%, with obesity alone at 6.7%.
Preprint · not peer-reviewed -
Tomorrow's worldInnovation in treatment new
Oral orforglipron is tested for cardiovascular safety against insulin in type 2 diabetes
A phase 3 trial randomised 2749 adults with type 2 diabetes and heart or kidney disease to oral orforglipron or insulin glargine, and followed them for a median two years.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Weight loss in impaired glucose tolerance went with fewer deaths over 34 years
In 540 Chinese adults with impaired glucose tolerance, a weight loss of 5% or more over six years carried a hazard ratio for death of 0.67 against no weight loss.
Peer-reviewed -
Behavioural scienceAdherence and persistence refines
Tirzepatide initiators stayed on treatment longer than semaglutide initiators
In propensity-matched US claims data on adults with type 2 diabetes, 12-month adherence was 60% for tirzepatide initiators against 45% for semaglutide initiators among GLP-1-naive patients, with persistence of 62% against 47%.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
GLP-1 prescribing to US children aged 8-11 with obesity rose but stayed under 1%
Among 3.5 million US children aged 8 to 11 with obesity and without diabetes recorded in Epic Cosmos between 2019 and June 2026, 0.6% received a GLP-1 receptor agonist prescription, with rates highest among 11-year-olds, girls, and those with obesity-related comorbidities.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Oral GLP-1 tablet safiglipron cut HbA1c by up to 1.45 points in type 2 diabetes
In the OUTSTAND-1 trial, once-daily safiglipron tablets lowered HbA1c by up to 1.45 percentage points more than placebo over 32 weeks in untreated type 2 diabetes.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
Lower education was the most consistent marker of obesity in Korean adults
Analysis of Korea's national health and nutrition survey for 2022 to 2024 found lower education the most consistent marker of obesity in adults, with income and employment less consistent.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Kidney disease progressed less often on a GLP-1 drug plus SGLT2 inhibitor
Among 32,448 matched adults with chronic kidney disease, those adding a GLP-1 drug to an SGLT2 inhibitor had 0.70 times the rate of kidney disease progression over a median year.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
Swiss children with obesity from poorer areas arrive with worse cardiometabolic risk
Among 886 children treated for obesity in Bern, ten points higher on the neighbourhood socioeconomic index was associated with lower obesity severity and lower odds of insulin resistance (OR 0.80).
Preprint · not peer-reviewed -
Health todayHeart and stroke refines
New heart failure was slightly less common on tirzepatide than semaglutide
Among 424,269 matched pairs of patients with obesity in the TriNetX records, one-year new-onset heart failure was 1.0% on tirzepatide and 1.3% on semaglutide.
Preprint · not peer-reviewed